The AUR87A study, conducted across 29 hospitals in the UK, EU, USA, and Canada, evaluates the use of glycosaminoglycans (GAGomes) as urine-derived metabolic biomarkers to monitor kidney cancer recurrence in patients following surgery.

The intermediary results show that the test correctly identified 90% of patients with recurrent cancer. Notably, a negative score corresponded to a 97% probability of being recurrence-free.

This high negative predictive value supports Elypta’s belief that post-treatment monitoring of cancer patients needs to be transformed, they state. Instead of undergoing repeated radiological exams – a process that can both expose the patient to radiation and constitute a significant burden – patients could submit a simple urine sample.

“These findings show the potentially transformative impact a urine-based test may have in the surveillance of recurrent disease for kidney cancer patients,” says Karl Bergman, Elypta CEO.

“A urine test can offer a less invasive and more comfortable alternative for post-operative monitoring, potentially transforming kidney cancer follow-up care,” said Volker Liebenberg, Chief Medical Officer at Elypta.

While the test is currently designated for research use only, this encouraging data from the AUR87A study underscores its potential to enhance patient care and streamline clinical protocols, describes Elypta.

The study’s second patient cohort is nearing final recruitment, with validation results expected later this year.